Namwiwat Medical PCL (BKK:NAM) Piotroski F-Score: 4 (As of Jul. 07, 2026) — 20% Below Median


BKK:NAM Namwiwat Medical Corp PCL BKK:NAM
40 GF Score
Price ฿3.40
GF Value ฿6.04
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Namwiwat Medical PCL Piotroski F-Score?

Namwiwat Medical PCL BKK:NAM -1.73% 40 Piotroski F-Score is 4 as of Jul. 07, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates BKK:NAM with a GF Score™ of 40/100 and a GF Value™ of ฿6.04 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 808 Medical Devices & Instruments companies, Namwiwat Medical PCL ranks worse than 56.68% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Namwiwat Medical PCL has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Namwiwat Medical PCL's Piotroski F-Score or its related term are showing as below:

BKK:NAM' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 5   Max: 7
Current: 4

During the past 6 years, the highest Piotroski F-Score of Namwiwat Medical PCL was 7. The lowest was 4. And the median was 5.

Namwiwat Medical PCL  (BKK:NAM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Namwiwat Medical PCL Piotroski F-Score Related Terms


Namwiwat Medical PCL Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Namwiwat Medical PCL's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Namwiwat Medical PCL Piotroski F-Score Chart

Namwiwat Medical PCL Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A N/A 5.00 4.00

Namwiwat Medical PCL Quarterly Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 5.00 4.00 4.00 4.00

BKK:NAM vs ABT, SYK, MDT: Piotroski F-Score Comparison

For the Medical Devices subindustry, Namwiwat Medical PCL's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Namwiwat Medical PCL Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Namwiwat Medical PCL's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Namwiwat Medical PCL's Piotroski F-Score falls into.


BKK:NAM
40GF Score
Namwiwat Medical Corp PCL BKK:NAM
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 12.451 + 22.101 + 30.791 + 12.151 = ฿77 Mil.
Cash Flow from Operations was -58.179 + 115.617 + -71.933 + 18.206 = ฿4 Mil.
Revenue was 389.499 + 487.2 + 454.98 + 376.87 = ฿1,709 Mil.
Gross Profit was 103.101 + 145.967 + 129.029 + 116.749 = ฿495 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(3169.907 + 2968.739 + 3067.998 + 3051.973 + 2885.694) / 5 = ฿3028.8622 Mil.
Total Assets at the begining of this year (Mar25) was ฿3,170 Mil.
Long-Term Debt & Capital Lease Obligation was ฿135 Mil.
Total Current Assets was ฿2,044 Mil.
Total Current Liabilities was ฿586 Mil.
Net Income was 40.047 + 70.855 + 56.695 + 60.922 = ฿229 Mil.

Revenue was 226.452 + 316.843 + 370.638 + 538.09 = ฿1,452 Mil.
Gross Profit was 91.004 + 146.045 + 139.761 + 170.303 = ฿547 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(2299.567 + 2342.609 + 2476.342 + 2709.052 + 3169.907) / 5 = ฿2599.4954 Mil.
Total Assets at the begining of last year (Mar24) was ฿2,300 Mil.
Long-Term Debt & Capital Lease Obligation was ฿92 Mil.
Total Current Assets was ฿2,374 Mil.
Total Current Liabilities was ฿790 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Namwiwat Medical PCL's current Net Income (TTM) was 77. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Namwiwat Medical PCL's current Cash Flow from Operations (TTM) was 4. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=77.494/3169.907
=0.02444677

ROA (Last Year)=Net Income/Total Assets (Mar24)
=228.519/2299.567
=0.0993748

Namwiwat Medical PCL's return on assets of this year was 0.02444677. Namwiwat Medical PCL's return on assets of last year was 0.0993748. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Namwiwat Medical PCL's current Net Income (TTM) was 77. Namwiwat Medical PCL's current Cash Flow from Operations (TTM) was 4. ==> 4 <= 77 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=134.748/3028.8622
=0.04448799

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=92.466/2599.4954
=0.03557075

Namwiwat Medical PCL's gearing of this year was 0.04448799. Namwiwat Medical PCL's gearing of last year was 0.03557075. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=2043.564/585.836
=3.48828682

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=2374.097/789.723
=3.00624016

Namwiwat Medical PCL's current ratio of this year was 3.48828682. Namwiwat Medical PCL's current ratio of last year was 3.00624016. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Namwiwat Medical PCL's number of shares in issue this year was 700. Namwiwat Medical PCL's number of shares in issue last year was 700. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=494.846/1708.549
=0.28962939

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=547.113/1452.023
=0.37679362

Namwiwat Medical PCL's gross margin of this year was 0.28962939. Namwiwat Medical PCL's gross margin of last year was 0.37679362. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1708.549/3169.907
=0.53899026

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1452.023/2299.567
=0.63143322

Namwiwat Medical PCL's asset turnover of this year was 0.53899026. Namwiwat Medical PCL's asset turnover of last year was 0.63143322. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+0+1+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Namwiwat Medical PCL has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Namwiwat Medical PCL (BKK:NAM) has a Piotroski F-Score of 4 as of Jul. 07, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Namwiwat Medical PCL and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Namwiwat Medical PCL's Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Namwiwat Medical PCL ranks #458 out of 808 companies in the Medical Devices & Instruments industry, placing it in the top 56.7%.
Is Namwiwat Medical PCL's Piotroski F-Score too high?
Namwiwat Medical PCL's current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Namwiwat Medical PCL's value of 4 is 20% below this industry median. Based on the distribution chart, Namwiwat Medical PCL ranks #458 out of 808 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Namwiwat Medical PCL has a GF Score™ of 40/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Namwiwat Medical PCL ranks #458 out of 808 companies for Piotroski F-Score. This places Namwiwat Medical PCL in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Namwiwat Medical PCL's value of 4 is 20% below this benchmark. Historically, Namwiwat Medical PCL's own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Namwiwat Medical PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Namwiwat Medical PCL's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Namwiwat Medical PCL and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Namwiwat Medical PCL's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿6.04, compared to a current price of ฿3.40 — trading 43.7% below its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Medical Devices & Instruments industry median of 5.00. Namwiwat Medical PCL's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current Piotroski F-Score is 4 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?

Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued. The current stock price of ฿3.40 is trading 43.7% below its estimated GF Value™ of ฿6.04. GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.

Key valuation signals for BKK:NAM:

  • Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
  • GF Value™: ฿6.04 vs. price of ฿3.40 (43.7% below fair value)
  • GF Score™: 40/100 with 5 warning signs
  • Industry Position: 20% below the Medical Devices & Instruments median (#458 of 808)

No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Namwiwat Medical PCL Business Description

Address 999/3-5 Moo 9 Prachauthit - Ku Sang Road, Nai Khlong Bang Pla Kot, Phra Samut Chedi, Samut Prakan, THA, 10290
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
40GF Score

Get the complete analysis for BKK:NAM

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿3.40
Price
฿6.04
GF Value